Deepika Garg1, Richard Grazi2, Geralyn M Lambert-Messerlian3, Zaher Merhi4. 1. Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY, 11219, USA. drgargdeepika@gmail.com. 2. Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY, 11219, USA. 3. Departments of Pathology and Obstetrics and Gynecology, Women and Infants Hospital, Alpert, Medical School at Brown University, Providence, RI, USA. 4. Department of Obstetrics and Gynecology, NYU School of Medicine, New York, NY, 11014, USA.
Abstract
PURPOSE: The pro-inflammatory advanced glycation end products (AGEs) and their anti-inflammatory soluble receptors, sRAGE, play a role in the pathogenesis of PCOS. There is a correlation between vitamin D (vit D) and sRAGE in the serum, whereby vit D replacement increases serum sRAGE levels in women with PCOS, thus incurring a protective anti-inflammatory role. OBJECTIVE: This study aims to compare levels of sRAGE, N-carboxymethyl-lysine (CML; one of the AGEs), and 25-hydroxy-vit D in the follicular fluid (FF) of women with or without PCOS, and to evaluate the correlation between sRAGE and 25-hydroxy-vit D in the FF. MATERIAL AND METHODS: Women with (n = 12) or without (n = 13) PCOS who underwent IVF were prospectively enrolled. RESULTS: Women with PCOS had significantly higher anti-Mullerian hormone levels, higher number of total retrieved and mature oocytes, and higher number of day 3 and day 5 embryos formed. Compared to women without PCOS, women with PCOS had significantly lower FF sRAGE levels. In women with PCOS, in women without PCOS, and in all participants together, there was a significant positive correlation between sRAGE and 25-hydroxy-vit D. sRAGE positively correlated with CML in women without PCOS but not in women with PCOS. CONCLUSIONS: In women with PCOS, the low ovarian levels of the anti-inflammatory sRAGE suggest that sRAGE could represent a biomarker and a potential therapeutic target for ovarian dysfunction in PCOS. Whether there is a direct causal relationship between sRAGE and vit D in the ovaries remains to be determined.
PURPOSE: The pro-inflammatory advanced glycation end products (AGEs) and their anti-inflammatory soluble receptors, sRAGE, play a role in the pathogenesis of PCOS. There is a correlation between vitamin D (vit D) and sRAGE in the serum, whereby vit D replacement increases serum sRAGE levels in women with PCOS, thus incurring a protective anti-inflammatory role. OBJECTIVE: This study aims to compare levels of sRAGE, N-carboxymethyl-lysine (CML; one of the AGEs), and 25-hydroxy-vit D in the follicular fluid (FF) of women with or without PCOS, and to evaluate the correlation between sRAGE and 25-hydroxy-vit D in the FF. MATERIAL AND METHODS:Women with (n = 12) or without (n = 13) PCOS who underwent IVF were prospectively enrolled. RESULTS:Women with PCOS had significantly higher anti-Mullerian hormone levels, higher number of total retrieved and mature oocytes, and higher number of day 3 and day 5 embryos formed. Compared to women without PCOS, women with PCOS had significantly lower FF sRAGE levels. In women with PCOS, in women without PCOS, and in all participants together, there was a significant positive correlation between sRAGE and 25-hydroxy-vit D. sRAGE positively correlated with CML in women without PCOS but not in women with PCOS. CONCLUSIONS: In women with PCOS, the low ovarian levels of the anti-inflammatory sRAGE suggest that sRAGE could represent a biomarker and a potential therapeutic target for ovarian dysfunction in PCOS. Whether there is a direct causal relationship between sRAGE and vit D in the ovaries remains to be determined.
Entities:
Keywords:
Advanced glycation end products; PCOS; RAGE; Vitamin D; sRAGE
Authors: E M E W Heijnen; M J C Eijkemans; E G Hughes; J S E Laven; N S Macklon; B C J M Fauser Journal: Hum Reprod Update Date: 2005-08-25 Impact factor: 15.610
Authors: Cynthia Balion; Lauren E Griffith; Lisa Strifler; Matthew Henderson; Christopher Patterson; George Heckman; David J Llewellyn; Parminder Raina Journal: Neurology Date: 2012-09-25 Impact factor: 9.910
Authors: H Selimoglu; C Duran; S Kiyici; C Ersoy; M Guclu; G Ozkaya; E Tuncel; E Erturk; S Imamoglu Journal: J Endocrinol Invest Date: 2009-10-09 Impact factor: 4.256